Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Biogen Idec and Genentech announce restructuring of anti-CD20 collaboration agreement
Episode 55 with Dr. Michael Levy on the status of regenerative stem cell therapies for multiple sclerosis
An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity.
Mycophenolic acid inhibits IL-2-dependent T cell proliferation, but not IL-2-dependent survival and sensitization to apoptosis.
INF-β1b therapy modulates L-arginine and nitric oxide metabolism in patients with relapse remittent multiple sclerosis.
Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells.
Estriol preserves synaptic transmission in the hippocampus during autoimmune demyelinating disease.
Equivalent Gene Expression Profiles between Glatopa™ and Copaxone®.
Phase III study: Ocrelizumab significantly reduces disease activity in PPMS patients
Episode 44 with Dr. Monika Bradl on an animal model for neuromyelitis optica (NMO)
Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis.
Structure of the LINGO-1-anti-LINGO-1 Li81 antibody complex provides insights into the biology of LINGO-1 and the mechanism of action of the antibody therapy.
20th Annual Rehabilitation In Multiple Sclerosis (RIMS) Conference
Drug reprofiling using zebrafish identifies novel compounds with potential pro-myelination effects.
American Society for Neurochemistry 47th Annual Meeting
Suppression of CD4+ T cell activation by a novel inhibitor of Src family kinases.
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.
Heartbleed Bug
Episode 61 with Dr. Yanming Wang on molecular imaging of the myelin sheathing of axons
Invitation to Share Your Thoughts on a New MS Research Resource
Direct immunomodulatory influence of IFN-β on human astrocytoma cells.
MS Research Roundup: May 16, 2014
An ADIOL-ERβ-CtBP transrepression pathway negatively regulates microglia-mediated inflammation.
Epigenetics in multiple sclerosis susceptibility: difference in transgenerational risk localizes to the major histocompatibility complex.
No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis.

Pages